According to AstraZeneca, it has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its Fluenz Tetra intranasal four-strain live attenuated influenza vaccine developed by its MedImmune subsidiary. Fluenz Tetra includes two strains of influenza A and two strains of influenza B. If approved, the vaccine would replace Fluenz in Europe beginning in the 2014-2015 flu season.
In the US, the vaccine is marketed as FluMist Quadrivalent and was approved by the FDA in February 2012.
MedImmune VP of Clinical Biologics Infectious Disease and Vaccines Filip Dubovsky commented, “We are delighted that Fluenz Tetra has received a positive opinion from the CHMP. The inclusion of two influenza B strains in the vaccine will provide broad protection and should help to reduce the overall incidence of influenza.”
Read the AZ press release.
